

Andrea Harrer

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/1301245/andrea-harrer-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

39
papers

657
citations

16
h-index

25
g-index

48
ext. papers

777
ext. citations

5.1
avg. IF

3.25
L-index

#	Paper	IF	Citations
39	Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.. <i>Multiple Sclerosis and Related Disorders</i> , 2022 , 59, 103560	4	2
38	Immune phenotyping study revealing caveats regarding a switch from fingolimod to cladribine. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 48, 102727	4	4
37	The CXCL13/CXCR5-chemokine axis in neuroinflammation: evidence of CXCR5+CD4 T cell recruitment to CSF. <i>Fluids and Barriers of the CNS</i> , 2021 , 18, 40	7	1
36	Chemokine CXCL13 in serum, CSF and blood-CSF barrier function: evidence of compartment restriction. <i>Fluids and Barriers of the CNS</i> , 2020 , 17, 7	7	6
35	Epitope competition and neutralizing antidrug antibodies: immune monitoring of antiprogrammed death-1 therapies and lessons learned from natalizumab. <i>British Journal of Dermatology</i> , 2020 , 183, 404	4	2
34	Beyond LNB: Real life data on occurrence and extent of CSF CXCL13 in neuroinflammatory diseases. <i>Journal of Neuroimmunology</i> , 2020 , 338, 577087	3.5	2
33	Neurological complications associated with influenza in season 2017/18 in Austria- a retrospective single center study. <i>Journal of Clinical Virology</i> , 2020 , 127, 104340	14.5	5
32	Cerebrospinal fluid CXCL13 indicates disease course in neuroinfection: an observational study. <i>Journal of Neuroinflammation</i> , 2019 , 16, 13	10.1	4
31	From natalizumab to fingolimod in eight weeks - Immunological, clinical, and radiological data in quest of the optimal switch. <i>Clinical Immunology</i> , 2017 , 176, 87-93	9	6
30	Elevated Toll-Like Receptor-Induced CXCL8 Secretion in Human Blood Basophils from Allergic Donors Is Independent of Toll-Like Receptor Expression Levels. <i>PLoS ONE</i> , 2016 , 11, e0149275	3.7	5
29	CD1d expression on chronic lymphocytic leukemia B cells affects disease progression and induces T cell skewing in CD8 positive and CD4CD8 double negative T cells. <i>Oncotarget</i> , 2016 , 7, 49459-49469	3.3	7
28	The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions. <i>BioMed Research International</i> , 2016 , 2016, 8232830	3	9
27	Human Cerebrospinal Fluid Promotes Neuronal Viability and Activity of Hippocampal Neuronal Circuits In Vitro. <i>Frontiers in Cellular Neuroscience</i> , 2016 , 10, 54	6.1	10
26	Basophil Reactivity as Biomarker in Immediate Drug Hypersensitivity Reactions-Potential and Limitations. <i>Frontiers in Pharmacology</i> , 2016 , 7, 171	5.6	15
25	Importance of cerebrospinal fluid analysis in the era of McDonald 2010 criteria: a German-Austrian retrospective multicenter study in patients with a clinically isolated syndrome. <i>Journal of Neurology</i> , 2016 , 263, 2499-2504	5.5	35
24	High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2015 , 180, 383-92	6.2	16
23	Serial flow cytometric analyses of blood and cerebrospinal fluid in natalizumab-associated progressive multifocal leukoencephalopathy with an excellent outcome. <i>Clinical and Experimental Neuroimmunology</i> , 2015 , 6, 172-174	0.4	0

22	Adaptive Immune Responses in a Multiple Sclerosis Patient with Acute Varicella-Zoster Virus Reactivation during Treatment with Fingolimod. <i>International Journal of Molecular Sciences</i> , 2015 , 16, 21832-45	6.3	7
21	Natalizumab saturation: biomarker for individual treatment holiday after natalizumab withdrawal?. <i>Acta Neurologica Scandinavica</i> , 2014 , 129, e12-5	3.8	18
20	High-dose intravenous interferon-beta in multiple sclerosis patients with high-titer neutralizing antibodies (HINABS II) - A pilot study. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 220-6	4	2
19	TaqManR proximity ligation technology for the detection of heterodimeric adhesion receptors on lymphocytes. <i>Journal of Immunological Methods</i> , 2014 , 404, 81-6	2.5	2
18	Tumefactive MS lesions under fingolimod: a case report and literature review. <i>Neurology</i> , 2013 , 81, 1654-8	6.5	61
17	Glatiramer acetate attenuates the pro-migratory profile of adhesion molecules on various immune cell subsets in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2013 , 173, 381-9	6.2	24
16	Circadian rhythmicity of inflammatory serum parameters: a neglected issue in the search of biomarkers in multiple sclerosis. <i>Journal of Neurology</i> , 2013 , 260, 221-7	5.5	24
15	Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1209-12	5	59
14	Current therapies in ischemic stroke. Part B. Future candidates in stroke therapy and experimental studies. <i>Drug Discovery Today</i> , 2012 , 17, 671-84	8.8	21
13	Isolated leptomeningeal infiltration of a primary CNS B-cell lymphoma diagnosed by flow cytometry and confirmed by necropsy. <i>Acta Neurologica Scandinavica</i> , 2012 , 126, e11-6	3.8	6
12	Current therapies in ischemic stroke. Part A. Recent developments in acute stroke treatment and in stroke prevention. <i>Drug Discovery Today</i> , 2012 , 17, 296-309	8.8	46
11	Lymphocyte subsets show different response patterns to in vivo bound natalizumab—a flow cytometric study on patients with multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e31784	3.7	18
10	Molecular evidence of transient therapeutic effectiveness of natalizumab despite high-titre neutralizing antibodies. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 506-9	5	6
9	Reshaping the Bet v 1 fold modulates T(H) polarization. <i>Journal of Allergy and Clinical Immunology</i> , 2011 , 127, 1571-8.e9	11.5	40
8	Basophil activation test for investigation of IgE-mediated mechanisms in drug hypersensitivity. <i>Journal of Visualized Experiments</i> , 2011 ,	1.6	9
7	Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. <i>Journal of Neuroimmunology</i> , 2011 , 234, 148-54	3.5	24
6	Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options. <i>Drug Discovery Today</i> , 2011 , 16, 8-21	8.8	7
5	Molecular characterization of Api g 2, a novel allergenic member of the lipid-transfer protein 1 family from celery stalks. <i>Molecular Nutrition and Food Research</i> , 2011 , 55, 568-77	5.9	23

4	Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 16-23	5	24
3	Characterization of plant food allergens: an overview on physicochemical and immunological techniques. <i>Molecular Nutrition and Food Research</i> , 2010 , 54, 93-112	5.9	30
2	Diclofenac hypersensitivity: antibody responses to the parent drug and relevant metabolites. <i>PLoS ONE</i> , 2010 , 5, e13707	3.7	39
1	Isoform identification and characterization of Art v 3, the lipid-transfer protein of mugwort pollen. <i>Molecular Immunology</i> , 2009 , 46, 1919-24	4.3	38